Answers are grounded in this paper and cite their sources.
The significantly altered metabolites can be used to differentiate (1) PD patients from healthy controls with high accuracy and (2) the stable PD with no dementia group from those with incipient dementia. Following further validation in larger cohorts, these metabolites could be used for both discrimination and establishing prognosis in PD.
No takes yet. Share an insight, caveat, or question.
Han et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: